TERF1 and lung carcinoma: In summary, the results described here are proof of concept that TRF1 abrogation is an effective therapeutic strategy to block the growth of aggressive lung carcinomas independently of telomere length and p53 status and that it is possible to achieve this by small molecules that are able to target TRF1 in vivo.